Atazanavir/ritonavir: a valuable once-daily HIV protease inhibitor with little impact on lipid profile

Author： Gianotti Nicola   Lazzarin Adriano  

Publisher： Future Medicine

ISSN： 1746-0794

Source： Future Virology, Vol.2, Iss.2, 2007-03, pp. : 131-143

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Elvitegravir: a once-daily inhibitor of HIV-1 integrase

By Wills Todd   Vega Vivian  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 3, 2012-03 ,pp. : 395-401

Informa Healthcare

Access to resources Recommend Favorite

Review of atazanavir: a novel HIV protease inhibitor

By Fuster Daniel   Clotet Bonaventura  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 9, 2005-08 ,pp. : 1565-1572

Informa Healthcare

Access to resources Recommend Favorite

Atazanavir: a novel HIV-1 protease inhibitor

By Piliero Peter J  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 9, 2002-09 ,pp. : 1295-1301

Informa Healthcare

Access to resources Recommend Favorite

Meta-analysis of once-daily and twice-daily lopinavir/ritonavir combined with NRTIs in HIV-1-infected, antiretroviral-naive patients

By van Wyk Jean   Qaqish Roula   Hollar Kimberly   White Kelly   D’’Amico Ronald   Norton Michael   Chiu Yi-Lin   King Martin  

Future Virology, Vol. 7, Iss. 1, 2012-01 ,pp. : 103-113

Future Medicine

Access to resources Recommend Favorite

Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment

By Barragan Patricia   Podzamczer Daniel  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 13, 2008-09 ,pp. : 2363-2375

Informa Healthcare

Access to resources Recommend Favorite